In Vivo Imaging of [60]Fullerene-Based Molecular Spherical Nucleic Acids by Positron Emission Tomography

• Published in: Molecular pharmaceutics Vol. 20; no. 10; pp. 5043 - 5051
• Main Authors: Äärelä, Antti, Auchynnikava, Tatsiana, Moisio, Olli, Liljenbäck, Heidi, Andriana, Putri, Iqbal, Imran, Lehtimäki, Jyrki, Rajander, Johan, Salo, Harri, Roivainen, Anne, Airaksinen, Anu J., Virta, Pasi
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 02.10.2023
• Subjects: PET-imaging; molecular spherical nucleic acids; delivery; nanoparticles
• ISSN: 1543-8384; 1543-8392
• DOI: 10.1021/acs.molpharmaceut.3c00370

18F-Labeled [60]­fullerene-based molecular spherical nucleic acids (MSNAs), consisting of a human epidermal growth factor receptor 2 (HER2) mRNA antisense oligonucleotide sequence with a native phosphodiester and phosphorothioate backbone, were synthesized, site-specifically labeled with a positron emitting fluorine-18 and intravenously administrated via tail vein to HER2 expressing HCC1954 tumor-bearing mice. The biodistribution of the MSNAs was monitored in vivo by positron emission tomography/computed tomography (PET/CT) imaging. MSNA with a native phosphodiester backbone (MSNA-PO) was prone to rapid nuclease-mediated degradation, whereas the corresponding phosphorothioate analogue (MSNA-PS) with improved enzymatic stability showed an interesting biodistribution profile in vivo. One hour after the injection, majority of the radioactivity was observed in spleen and liver but also in blood with an average tumor-to-muscle ratio of 2. The prolonged radioactivity in blood circulation may open possibilities to the targeted delivery of the MSNAs.